HCPCS Level II · July 2026
New HCPCS Level II Codes for July 2026
Effective . 40 new codes in this release.
← All changes in July 2026| Code | Description |
|---|---|
| A9574 | Injection, ferumoxytol, 1 mg |
| C1609 | Vertebral device, motion-preserving, with screw fixation |
| C8014 | Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, including use of a suction enabled ureteral access sheath, with irrigation (if performed) |
| C9310 | Injection, leucovorin calcium (avyxa), 1 mg |
| G0574 | Management of new patient with dementia residing in an eligible residential care community, for use only in a medicare-approved cmmi model (services must be furnished within a patient's eligible residential care community, including assisted living facilities, board and care homes, or other qualifying residential settings where dementia care services are provided) |
| G0575 | Management of established patient with dementia residing in an eligible residential care community, for use only in a medicare-approved cmmi model (services must be furnished within a patient's eligible residential care community, including assisted living facilities, board and care homes, or other qualifying residential settings where dementia care services are provided) |
| G0577 | Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction performed in the non-facility setting |
| G0669 | Outcome-aligned payment (oap) for technology-enabled chronic care management of early cardio-kidney-metabolic (eckm) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); initial 12-month period; per month |
| G0670 | Outcome-aligned payment (oap) for technology-enabled chronic care management of early cardio-kidney-metabolic (eckm) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); follow-on 12-month period; per month |
| G0671 | Outcome-aligned payment (oap) for technology-enabled chronic care management of cardio-kidney-metabolic (ckm) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); initial 12-month period; per month |
| G0672 | Outcome-aligned payment (oap) for technology-enabled chronic care management of cardio-kidney-metabolic (ckm) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); follow-on 12-month period; per month |
| G0673 | Outcome-aligned payment (oap) for technology-enabled chronic care management of musculoskeletal (msk) conditions (chronic musculoskeletal pain); initial 12-month treatment period; per month |
| G0674 | Outcome-aligned payment (oap) for technology-enabled chronic care management of behavioral health (bh) conditions (one or more of: depression, anxiety); initial 12-month period; per month |
| G0675 | Outcome-aligned payment (oap) for technology-enabled chronic care management of behavioral health (bh) conditions (one or more of: depression, anxiety); follow-on 12-month period; per month |
| G0676 | Standard co-management service payment for documented review of clinical updates from access participant managing cardio-kidney-metabolic conditions (early cardio-kidney-metabolic [eckm] or cardio-kidney-metabolic [ckm] track); per review |
| G0677 | Standard co-management service payment for documented review of clinical updates from access participant managing musculoskeletal (msk) conditions; per review |
| G0678 | Standard co-management service payment for documented review of clinical updates from access participant managing behavioral health (bh) conditions (depression, anxiety); per review |
| J0528 | Injection, fosfomycin disodium, 20 mg |
| J1289 | Injection, narsoplimab-wuug, 1 mg |
| J1577 | Injection, immune globulin (qivigy), 100 mg |
| J2361 | Injection, depemokimab-ulaa, 1 mg |
| J2374 | Apraclonidine hydrochloride ophthalmic, 1% solution, 0.1 ml |
| J2789 | Riboflavin 5'-phosphate, ophthalmic solution (epioxahd/epioxa), up to 2 ml |
| J3386 | Injection, etuvetidigene autotemcel, per treatment |
| J3405 | Injection, onasemnogene abeparvovec-brve, per treatment |
| J7176 | Injection, human fibrinogen - chmt (fesilty), 1 mg |
| J9053 | Injection, belantamab mafodotin-blmf, 0.1 mg |
| J9062 | Injection, amivantamab 5 mg and hyaluronidase-lpuj |
| J9232 | Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg |
| M0231 | Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, first dose |
| M0232 | Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose |
| Q0234 | Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg |
| Q5164 | Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg |
| Q5165 | Injection, denosumab-mobz (oziltus), biosimilar, 1 mg |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg |
| Q5167 | Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg |
| Q5168 | Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg |
| Q5170 | Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg |
| Q5171 | Injection, denosumab-mobz (boncresa), biosimilar, 1 mg |